...By Paul Bonanos, Associate Editor With early efficacy signals emerging from a dose-finding study, Cyteir will...
...the only one in its class to reach the clinic.RA Capital led the round for Cyteir Therapeutics Inc....
...present data from the dose-escalation portion of a Phase I/II trial at a future medical meeting.Cyteir’s...

...been watching for a while, according to Novo Ventures’ Karen Hong, who joined Cyteir’s board. “Cyteir...
...April, Cyteir had reopened its B round. “The timing was excellent,” Hong said, noting that Cyteir...
...functions while preventing it from participating in DNA damage repair (see “Cyteir: Stopping Shape-Shifters” ). Cyteir...

...describe synthetic lethal interactions involving the phosphatase DUSP1 ( No. 51 and No. 1341 ). Cyteir Therapeutics Inc....
...Therapeutics Inc., Watertown, Mass. Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Cleveland Clinic, Cleveland, Ohio Cyteir Therapeutics Inc....

...company BioAxone BioSciences Inc. (Cambridge, Mass.) hired Ronald Goldstein as CFO. He was CFO at Cyteir Therapeutics Inc....

...Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
...joined the company’s board. Celgene’s Maria Palmisano joined as a board observer. Cyteir Therapeutics Inc., Cambridge, Mass. Alicia Parker Cyteir Therapeutics Inc....

...Existing investor Celgene Corp. (NASDAQ:CELG) participated alongside new investors Lightstone Ventures and DROIA Oncology Ventures. Cyteir...
...Bart Van Hooland joined the company’s board. Celgene’s Maria Palmisano joined as a board observer. Alicia Parker Cyteir Therapeutics Inc....

...DNA repair enzymes. Cyteir said it will develop the compounds for cancer and autoimmune diseases. Cyteir...
...or royalties. Jackson did not respond to inquiries. The Jackson Laboratory , Bar Harbor, Maine Cyteir Therapeutics Inc....

...preclinical development of new chemical entities derived from the RAD51 inhibitor used in the study. Cyteir Therapeutics Inc.'s...
...other AID-overexpressing malignancies. SciBX 6(22); doi:10.1038/scibx.2013.544 Published online June 6, 2013 Patent pending; licensed to Cyteir...

...chance to work. "Genomic instability is one of the most defining features of tumors," said Cyteir...
...NSCLC). In 2011, iniparib failed in a Phase III trial in metastatic triple-negative breast cancer. Cyteir...
...the proof-of-concept findings in the Journal of Experimental Medicine in April. Last year, Mills launched Cyteir...